AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza ...

Coming in first on the list of Top 25 Pharma Companies US Rx is AbbVie, reaching $41,857m in US Rx revenue in 2023 and ...

Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.

Ono – which acquired rights to Romvimza when it bought Deciphera Pharma in a $2.4 billion deal that closed in 2023 – said ...

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

Thank you very much for waiting. We will now would like to start Daiichi Sankyo's Financial Results Briefing for the Third Quarter of Fiscal Year 2024. My name is Asakura from Corporate ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a report ...

The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...

The rising global cancer incidence is a key factor driving the CD47 inhibitors market, as the demand for novel therapies grows. Recent clinical trial ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor type.